Table 2: Changes in patient's neurological state (motor impairments, involuntary movements, and associated disorders) measured at baseline, intervention/follow-up (FU) visits and at the end of study FU visit.
|
|
Baseline |
Month 1 FU (post Inf 2) |
Month 3 FU (post Inf 6) |
Month 4 FU (post Inf 8) |
Month 6 (Inf 9) |
Month 9 (Inf 12) |
Month 6 (Inf 9) |
Month 15 (Inf 18) |
Month 18 (Inf 21) |
Month 21 (Inf 24) |
Month 24 (Inf 27) |
Month 27 (Inf 30) |
Month 30 FU (Post Inf 32) |
|
Motor Impairment
|
|
|
|||||||||||
|
Spasticity |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
|
Ataxia |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
|
Involuntary Movement |
|||||||||||||
|
Athetosis |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✔ |
✔ |
|
Dystonia |
✗ |
✗ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Associated Disorders |
|
||||||||||||
|
Dysphagia |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
|
Visual Impairment |
✗ |
✗ |
✗ |
✗ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Neuropsychological Disorders |
✗ |
✗ |
✗ |
✗ |
✗ |
✔ |
✗ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Cognitive Impairment |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
✗ |
|
Gastroesophageal Reflux |
* |
* |
* |
* |
* |
* |
✗ |
✗ |
✗ |
✗ |
✔ |
✔ |
✔ |
The table shows the indication of motor impairment along with several other CP-associated disorders (represented with '✗'). With the administration of HB-adMSCs therapy, some of the disorders started to resolve (e.g., elimination of Dystonia was observed after 6 infusions; represented by '✔') and over the course of the study (total of 32 infusions), many of the CP-associated disorders were alleviated (indicated by '✔'). FU: Follow-up, post-inf: post-infusion.